Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond

Expert Review of Anticancer Therapy

Volumn 6, Issue 3, 2006, Pages 361-371

  Montalban, Carlos ^a   Norman, Francesca ^b  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Gastric lymphoma; Helicobacter pylori; Lymphoma; MALT; MALT lymphoma

Indexed keywords

ALKYLATING AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH CITRATE; CD20 ANTIBODY; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; METRONIDAZOLE; MITOXANTRONE; PREDNISONE; PROTON PUMP INHIBITOR; PURINE DERIVATIVE; RITUXIMAB; TETRACYCLINE; VINCRISTINE SULFATE; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; PROTON PUMP;

ADVANCED CANCER; B CELL LYMPHOMA; BACTERIAL COLONIZATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER STAGING; CANCER THERAPY; CHROMOSOME TRANSLOCATION 11; CHROMOSOME TRANSLOCATION 18; DISEASE ASSOCIATION; ENDOSCOPIC ECHOGRAPHY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; MINIMAL RESIDUAL DISEASE; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; REVIEW; SEROSA; STOMACH LYMPHOMA; STOMACH SURGERY; STOMACH WALL; TUMOR LOCALIZATION; TUMOR REGRESSION; DRUG ANTAGONISM; MICROBIOLOGY; PROGNOSIS;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ENZYME INHIBITORS; HELICOBACTER INFECTIONS; HUMANS; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; PROGNOSIS; PROTON PUMPS;

EID: 33644920949     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.6.3.361     Document Type: Review

References (80)

1. Isaacson PG, Wright DH. Malignant lymphomas of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52, 1410-1416 (1983).
2. Isaacson PG. Gastric MALT lymphoma: from concept to cure. Ann. Oncol. 10, 637-645 (1999).
3. Harris NL, Jaffe E, Stein H et al. A Revised European-American Classification of Lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361-1392 (1994).
4. Harris NL, Jaffe E, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. J. Clin. Oncol. 17, 3835-3849 (1999).
5. International Lymphoma Study Group. The Non-Hodgkin's Classification Project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89, 3909-3918 (1997).
6. Koch P, del Valle F, Berdel WE et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomical and histological distribution, clinical features and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J. Clin. Oncol. 19, 3861-3873 (2001).
7. Ullrich A, Fischbach, Blettner M. Incidence of gastric B-cell lymphomas: a population-based study in Germany. Ann. Oncol. 13, 1120-1127, (2002).
8. Isaacson PG, Muller-Hermelink HK, Piris MA et al. Extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tisue (MALT) lymphoma. In: Tumours of Haematopoietic and Lymphoid Issues. World Health Organization Classification of tumours. IARC Press, Lyon, France. 157-160 (2001).
9. Dierlamm J, Baens M, Woldarska I et al. The apoptosis inhibitor gene AP12 and a novel gene, MLT are recurrently rearranged in the t(11;18) associated with the mucosa-associated lymphoid tissue lymphoma. Blood 93, 3601-3609 (1999).
10. Ott G, Katzberger T, Greiner A et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not in high-grade malignant non-Hodgkin's lymphomas of the mucosa associated lymphoid tissue (MALT) type. Cancer. Res. 57, 3944-3948 (1997).
11. Liu H, Ye H, Dogan A. T(11;18)8q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 98, 1182-1187 (2001).
12. Farinha P, Gascoyne R. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J. Clin. Oncol. 23, 6370-6378 (2005).
13. Willis TG, Jadayel DM, Du MQ et al. Bcl-10 is involved in t(1:14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96, 35-45 (1999).
14. Starostik P, Patzner J, Greiner A et al. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways. Blood 99, 3-9 (2002).
15. Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N. Eng. J. Med. 330, 1267-1271 (1994).
16. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet 338, 1175-1176 (1991).
17. Hussel T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342, 571-574 (1993).
18. Wotherspoon A, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of helicobacter pylori. Lancet 342, 575-577 (1993).
19. Morgner A, Lehn N, Andersen LP et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenteology 118, 821-828 (2000).
20. Xu WS, Ho FCS, Chan ACL, Srivastava G. Pathogenesis of gastric lymphoma: the enigma in Hong Kong. Ann. Oncol. 8(Suppl. 2) S41-S44 (1997).
21. Luppi M, Longo G, Ferrari MG et al. Additional neoplasms and HCV infection in low grade lymphoma of the MALT type. Br. J. Haematol. 94, 373-375 (1996).
22. Tkoub EM, Haioum C, Paulotsky JM, Dhumeaux D, Delchier JC. Chronic hepatitis C virus and gastric MALT lymphoma. Blood 91, 360-369 (1998).
23. Montalban C, Castrillo JM, Abraira V et al. Gastric B-cell mucosa-associated lymphoid tissue (MALT) lymphoma. Clinicopathological study and evaluation of prognostic factors in 143 patients. Ann. Oncol. 6, 355-362 (1995).
24. Thieblemont C, Berger F, Dumontet C et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 95, 802-806 (2000).
25. Chan JC, NG CS, Isaacson P. Relationship between high-grade lymphoma and low grade B-cell mucosa-associated lymphoid tissue lymphoma (MALToma) of the stomach. Am. J. Pathol. 136, 1153-1164 (1990).
26. De Jong D, Boot H, Van Heerde P, Hart GAM, Taal BG. Histological grading in gastric lymphoma: pretreatment criteria and clinical relevance. Gastroenterology 112, 1466-1474 (1997).
27. Beal KP, Yeung KW, Yahalom J. FGD-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type. Ann. Oncol. 16, 473-480 (2005).
28. Rohatiner A, d'Amore F, Coiffier B et al. Report of a workshop convened to discuss the pathological staging classification of gastrointestinal tract lymphoma. Ann. Oncol. 5, 397-400 (1994).
29. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann. Intern. Med. 131, 88-95 (1999).
30. Roggero E, Zucca E, Pinnotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann. Intern. Med. 122, 767-769 (1995).
31. Bayerdörffer E, Neubauer A, Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of helicobacter pylori infection. Lancet 345, 1591-1594 (1995).
32. Montalban C, Manzanal A, Boixeda D et al. Helicobacter pylori eradication for the treatment of low grade gastric MALT lymphoma. Follow up together with sequential molecular studies. Ann. Oncol. 8(Suppl. 2), S37-S39 (1997).
33. Savio A, Franzin G, Wotherspoon AC et al. Diagnosis and post-treatment follow-up of helicobacter pylori-positive gastric lymphoma of the mucosa-associated lymphoid tissue: histology, polymerase chain reaction, or both? Blood 87, 1255-1260 (1996).
34. Ruskoné-Fourmestraux A, Lavergne A, Aegerter PH et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 48, 297-303 (2001).
35. De Jong D, Vyth-Dreese F, Dellemijn T et al. Histological and immunophenotipical parameters to predict treatment outcome of helicobacter pylori eradication in low-grade gastric MALT lymphoma. J. Pathol. 193, 318-324 (2001).
36. Liu H, Ye H, Ruskoné-Fourmestraux A et al. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 122, 1286-1294 (2002).
37. Ye H, Liu H, Attygalle A et al. Variable frequencies of t(11;18) (q21;q21) I MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102, 1012-1018 (2003).
38. Ye H, Liu H, Raderer M et al. High incidence of t(11;18)(q21;q21) in Helicobacter pylori negative gastric MALT lymphoma. Blood 101, 2547-2550 (2003).
39. Gisbert JP, Calvet X, Gomollón J, Monéa J, Grupo Conferencia Española de Consenso sobre Helicobacter pylori. Eradication treatment of helicobacter pylori. Recommendations of the II Spanish Consensus Conference. Med. Clin. 125, 301-316 (2005).
40. El-Zimaity HM, Wotherspoon A, de Jong D. Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus. Blood Cells Mol. Dis. 34, 6-16 (2005).
41. Copie-Bergman C, Gaulard P, Lavergne-Slove A et al. Proposal for a new histological grading system for post-treatment evaluation of gastric MALT lymphoma. Gut 52, 1656 (2003).
42. Montalban C, Santón A, Redondo C et al. Long-term persistence of molecular disease after histological remission in low grade gastric MALT lymphoma treated with H. pylori eradication. Lack of association with translocation t(11;18): a 10-year updated follow-up of a prospective study. Ann. Oncol. 16, 1539-1544 (2005).
43. Thiede C, Alpen B, Morgner A et al. Ongoing somatic mutations and clonal expansion after cure of Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J. Clin. Oncol. 16, 3822-3831 (1998).
44. Pinotti G, Zucca E, Roggero E et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk. Lymphoma 26, 527-537 (1997).
45. Montalban C, Castrillo JM, Lopez-Abente G et al. Other cancers in gastric MALT lymphoma. Leuk. Lymphoma 33, 161-168 (1999).
46. Issacson PG, Diss TC, Wotherspoon AC et al. Long term follow up of gastric MALT lymphoma treated by eradication of H. pylori with antibiotics. Gastroenterology. 117, 750-751 (1999).
47. Bertoni F, Conconi A, Capella C et al. Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. Blood 99, 2541-2544 (2002).
48. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53, 34-37 (2004).
49. Wündisch T, Tiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J. Clin. Oncol. 23, 8018-8024 (2005).
50. Thiede C, Wundisch T, Alpen B et al. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histological remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J. Clin. Oncol. 19, 1600-1609 (2001).
51. Salar A, Bellosillo B, Serrano S, Besses C. Persistent residual disease in t(11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. J. Clin. Oncol. 23, 7361-7362 (2005).
52. Finke J, Slanina J, Lange W, Dolken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J. Clin. Oncol. 11, 1668-1673 (1993).
53. Cogliati SB, Schmid U, Schumacher U et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology 101, 1159-1170 (1991).
54. Thiebelmont C, Dumontet C, Bouafia F et al. Outcome in relation to treatment modalities in 48 patients with localized gastric MALT lymphoma: a retrospective study of patients treated during 1976-2001. Leuk. Lymphoma 44, 257-262 (2003).
55. Zinzani PL, Tani M, Barbieri E et al. Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma. Haematologica 88, 128-129 (2003).
56. Fischbach W, Dragosics B, Kolve-Goebler ME et al. Primary gastric B-cell lymphoma: Results of a prospective multicenter study. Gastroenterology 119, 1191-1202 (2000).
57. Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med. Oncol. 22, 57-62 (2005).
58. Koch P, del Valle F, Berdel W, et al. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma. Results of the prospective German Multicenter Study GIT NHL 01/92. J. Clin. Oncol. 18, 3874-3883 (2001).
59. Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the german multicenter study (GIT NHL 02/96). J. Clin. Oncol. 23, 7050-7059, (2005).
60. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J. Clin. Oncol. 22, 4157-4164 (2003).
61. Schechter N, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with 9radiation alone. J. Clin. Oncol. 16, 1916-1921 (1998).
62. Noy A, Yahalom J, Zaretsky, Brett I, Zelenetz D. Gastric mucosa-associated lymphoid tissue lymphoma detected clonotypic polymerase chain reaction despite continuous pathologic emission induced by involved-field radiotherapy. J. Clin. Oncol. 23, 3768-3772 (2005).
63. Hammel P, Haioum C, Chaumette MT et al. Efficacy of single agent chemotherapy in low grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J. Clin. Oncol. 13, 2524-2529 (1995).
64. Wohrer S, Drach J, Hejna M et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). Ann. Oncol. 14, 1758-1761 (2003).
65. Jager G, Neumeister P, Brezinschek R et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT)-type with cladribine (2-Chlorodeoxyadenosine): a phase II study. J. Clin. Oncol. 18, 3872-3877(2002).
66. Zinzani PL, Stefoni V, Musuraca G et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue. Cancer 100, 2190-2194 (2004).
67. Raderer M, Jager G, Brugger S et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 65, 306-310 (2003).
68. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102, 2741-2745 (2003).
69. Martinelli G, Laszlo D, Ferreri AJM et al. Clinical activity of rituximab in gastric marginal zone lymphoma non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J. Clin. Oncol. 23, 1979-1983 (2005).
70. Avilés A, Nambo MJ, Neri N et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann. Surg. 240, 44-50, (2004).
71. Binn M, Ruskoné-Fourmestraux A, Lepage E et al. Surgical resection plus chemotherapy versus chemotherapy alone: comparison of two strategies to treat large B-cell gastric lymphoma. Ann. Oncol. 14, 1751-1757 (2003).
72. Ibrahim EM, Ezzat AA, Raja MA et al. Primary gastric non-Hodgkin's lymphoma: clinical features, management and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann. Oncol. 10, 1441-1449 (1999).
73. Raderer M, Chott A, Drach J et al. Chemoterapy for management of localised high-grade gastric B-cell lymphoma: how much is necessary? Ann. Oncol. 13, 1094-1098 (2002).
74. Wohrer S, Puspok A, Drach J et al. Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) for treatment of early-stage gastric diffuse large B-cell lymphoma. Ann. Oncol. 15, 1086-1090 (2004).
75. Morgner A, Miehlke S, Fischbach W et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J. Clin. Oncol. 19, 2041-2048 (2001).
76. Chen LT, Lin JT, Shyu RY et al. Prospective study of Helicobacter pylori eradication therapy in stage IE high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J. Clin. Oncol. 19, 4245-4251 (2001).
77. Boot H, de Jong D, van Herdee P, Taal BG. The role of helicobacter pylori in high grade MALT lymphoma. Lancet 346, 448-449 (1995).
78. Alpen B, Kuse R, Parwaresch R et al. Ongoing monoclonal B-cell proliferation is not common in gastric B-cell lymphoma after combined radiochemotherapy. J. Clin. Oncol. 22, 3039-3045 (2004).
79. Levy M, Copie-Bergman C, Gameiro C et al. Prognosis value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J. Clin. Oncol. 22, 5061-5066 (2005).
80. Streubel B, Ye H, Du MG et al. Translocation t(11;18))(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 100, 2190-2194 (2004).